

ADVISORY COMMITTEE
of the Connecticut Bioscience Innovation Fund
Minutes – Regular Meeting
Wednesday, November 17, 2021

A regular meeting of the **Connecticut Bioscience Innovation Fund** (“the Bioscience Fund”) **Advisory Committee** (the “Committee”) was held electronically through Microsoft Teams on November 17, 2021.

1. Call to Order:

Noting the presence of a quorum, Matthew McCooe, Chairperson of the Committee, called the meeting to order at 10:03 a.m.

Committee Members Present: Peter Farina, Ph.D.; William LaRoche, Ph.D.; Matt McCooe; Alan Mendelson; Anthony Muyombwe, Ph.D.; Kevin Rakin; David Scheer; Jonathan Soderstrom, Ph.D; and Sandra Weller, Ph.D.

Absent: Charles Lee, Ph.D; Seth Feuerstein, M.D

Staff Attending: Kevin Crowley; Tamyra Davis; Cyndi Greene, Ph.D.; Stepheni Harpin; Peter Longo; Jordan Lue; Alison Malloy, Matthew McCooe; Pauline Murphy; Ted Murphy; Patrick O’Neill; Matthew Panicali (joined at 10:32 a.m.) Matthew Storeygard; Daniel Wagner; David Wurzer; and Wenping Zhou, Ph.D.

2. Approval of Minutes:

Mr. McCooe asked the Committee members to consider the minutes from the October 20, 2021 meeting

Upon a motion made by Dr. Soderstrom and seconded by Dr. Farina the Advisory Committee members voted unanimously in favor of adopting the minutes from the October 20, 2021 meeting, as presented.

3. New Investment Proposal:

Noting a potential conflict of interest, Dr. Farina, Dr. LaRoche and Dr. Soderstrom recused themselves from any discussion on Normunity, LLC. and left the meeting at 10:04 a.m.

“Normunity, LLC - New Haven, CT”

Mr. Wagner and Dr. Zhou presented the proposed new investment approval request for Normunity, LLC, a preclinical stage biotech company based on novel targets discovered for cancer immunology.

A discussion ensued.

Upon a motion made by Mr. McCooe, seconded by Mr. Rakin, the Advisory Committee members voted 5:1 in favor of approving the financing by the Connecticut Bioscience Innovation Fund (“CBIF”) in an amount of up to TWO MILLION DOLLARS (\$2,000,000), as presented, in Normunity, LLC.

Noting a potential conflict of interest, Mr. Rakin recused himself from any discussion on Halda Therapeutics, LLC. and left the meeting at 10:33 a.m.

Dr. LaRochelle rejoined the meeting at 10:33 a.m.

4. Follow-on Investment Proposals:

“Halda Therapeutics, LLC. - New Haven, CT”

Mr. Wurzer and Dr. Zhou presented the proposed follow-on investment approval request for Halda Therapeutics, LLC. Mr. Wurzer then went on to discuss CI’s investment history with the company.

A discussion ensued.

Upon a motion made by Mr. McCooe, seconded by Dr. Scheer, the Advisory Committee members voted 5:1 in favor of approving the financing by the CBIF in an amount of up to ONE MILLION SEVEN HUNDRED FIFTY THOUSAND DOLLARS (\$1,750,000), as presented, in Halda Therapeutics, LLC.

Dr. Farina, Mr. Rakin and Dr. Soderstrom rejoined the meeting at 10:52 a.m.

“Project Well, Inc. - Stamford, CT”

Ms. Malloy reviewed the proposed follow-on investment approval request for Project Well, Inc. Ms. Malloy then went on to discuss CI’s investment history with the company.

A discussion ensued.

Upon a motion made by Dr. Weller, seconded by Dr. Farina, the Advisory Committee members voted unanimously in favor of approving the financing by the CBIF in an amount of up to ONE MILLION DOLLARS (\$1,000,000), as presented, in Project Well, Inc.

Mr. McCooe left the meeting at 10:59 a.m. and returned at 11:10 a.m.

“Torigen Pharmaceuticals, Inc. - Farmington, CT”

Mr. Crowley reviewed the proposed follow-on investment approval request for Torigen Pharmaceuticals, Inc. Mr. Crowley then went on to discuss CI’s investment history with the company.

A discussion ensued.

Upon a motion made by Mr. Rakin, seconded by Mr. McCooe, the Advisory Committee members voted unanimously in favor of approving the financing by the CBIF in an amount of up to FIVE HUNDRED THOUSAND DOLLARS (\$500,000), as presented, and for the maturity of the CBIF outstanding convertible note to be extended and made coterminous with the maturity of the new financing, in Torigen Pharmaceuticals, Inc.

5. Other Business:

There was no other business to report.

6. Date of Next Meeting:

December 22, 2021 at 10:00 a.m.

7. Adjournment:

Upon a motion made by Mr. Rakin, seconded by Dr. Weller, the Advisory Committee members voted unanimously in favor of adjourning the meeting at 11:25 a.m.

Respectfully Submitted,



[Matt McCooe \(Dec 22, 2021 12:28 EST\)](#)

Matthew McCooe

Chairperson






11-17-21 CBIF Minutes

Final Audit Report

2021-12-22

Created:	2021-12-22
By:	Stepheni Harpin (stepheni.harpin@ctinnovations.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAsdh-gMVtz_3KWX4XM0-UMWu9U_xUwZum

"11-17-21 CBIF Minutes" History

-  Document created by Stepheni Harpin (stepheni.harpin@ctinnovations.com)
2021-12-22 - 4:55:55 PM GMT- IP address: 68.1.171.209
-  Document emailed to Matt McCooe (matt.mccooe@ctinnovations.com) for signature
2021-12-22 - 4:56:18 PM GMT
-  Email viewed by Matt McCooe (matt.mccooe@ctinnovations.com)
2021-12-22 - 5:28:43 PM GMT- IP address: 24.188.198.78
-  Document e-signed by Matt McCooe (matt.mccooe@ctinnovations.com)
Signature Date: 2021-12-22 - 5:28:52 PM GMT - Time Source: server- IP address: 24.188.198.78
-  Agreement completed.
2021-12-22 - 5:28:52 PM GMT